Scott Gottlieb: Conflicts surround Trump’s FDA pick
From the article:
Even some industry watchdogs are cautiously optimistic. In a New England Journal of Medicine perspective, Rachel Sachs, a Washington University associate professor of law who studies the FDA, points to Gottlieb's former ties to industry as potentially positive.
"As someone who understands the drug development process from all sides, he will be more informed," said Sachs. "I'm going to wait to judge to see what policy decisions he comes to. Hopefully he has the agency's best interest at heart."
Read more here!biotechnology fda health care finance health law policy pharmaceuticals rachel sachs regulation